Evidence Supports Endocrine Therapy for ER-Low Breast Cancer

Patients with 6–10% estrogen receptor expression and residual disease may benefit most from therapy

Topline

A large national analysis suggests that endocrine therapy may significantly improve survival in patients with ER-low early breast cancer, particularly in those with 6–10% ER expression or residual disease after neoadjuvant chemotherapy.

Study Details

Endocrine therapy is a cornerstone of treatment for estrogen receptor-positive (ER+) breast cancer.…